Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review

The most frequent thromboprophylaxis option used for myeloma patients on lenalidomide-based therapy is ASA. However, ASA may not confer appropriate thromboprophylaxis in patients using RD, but may be a safe option with MPR. In future studies, the IMWG VTE risk stratification criteria should be validated, incorporating the thromboprophylaxis option accordingly. More studies comparing the efficacy and safety of ASA to LMWH are warranted.